Seattle Genetics, Inc. (Nasdaq: SGEN) today presented preclinical data on SGN-70 at the American College of Rheumatology (ACR) Annual Scientific Meeting in San Francisco, California. SGN-70 is a humanized monoclonal antibody...
The University of Kentucky Pharmacy and Medicine Continuing Education Office (UKPMCE) announced today the launch of the Rheumatoid Arthritis Educational Challenge (RAEC), which will address deficits in the treatment of...
Bristol-Myers Squibb Company (NYSE: BMY) today announced at the American College of Rheumatology (ACR) Annual Scientific Meeting in San Francisco results from a 10-month study which showed that ORENCIA® (abatacept), compared to...
Results of the REFLEX study1 show that the number of people with rheumatoid arthritis (RA) achieving clinical remission from their disease doubled over three successive treatment courses with MabThera (rituximab) when used in...
UCB announced results from several Phase III clinical trials evaluating CIMZIA(R) (certolizumab pegol) - the only PEGylated anti-TNF (Tumor Necrosis Factor) - presented at the American College of Rheumatology (ACR) Annual...
More than half of patients receiving every four week subcutaneous injections of golimumab (CNTO 148) 50 mg and 100 mg, an investigational therapy, experienced sustained improvements in the joint and skin symptoms of active...
BOTHELL, Wash.----Seattle Genetics, Inc. today presented preclinical data on SGN-70 at the American College of Rheumatology Annual Scientific Meeting in San Francisco, California. SGN-70 is a humanized monoclonal antibody...
LUND, SWEDEN--(Marketwire - October 28, 2008) - Active Biotech (NASDAQ OMX Nordic: ACTI) has presented data regarding the 57-57 project at the American College of Rheumatology (ACR) Annual Scientific Meeting, a premier event...
SAN FRANCISCO, October 27, 2008 - Bristol-Myers Squibb Company (NYSE: BMY) today announced at the American College of Rheumatology (ACR) Annual Scientific Meeting in San Francisco results from a 10-month study which showed that...
Bristol-Myers Squibb Company (NYSE: BMY) today announced at the American College of Rheumatology (ACR) Annual Scientific Meeting in San Francisco results from a 10-month study which showed that ORENCIA® (abatacept), compared to...